Polymorphic forms of naltrexone
View Patent ↗This invention relates to the discovery of novel polymorphic forms of naltrexone, including solvates, hydrates, anhydrous and other crystalline forms and combinations thereof. These novel forms of naltrexone impart advantages in pharmaceutical formulations incorporating them, including sustained release, or long acting, formulations.
1. A crystalline naltrexone dichloromethane solvate which is characterized by at least one of:
(a) the x-ray powder diffraction pattern of FIG. 7A ;
(b) the differential scanning calorimetry thermogram of FIG. 19A ; and
(c) the IR-ATR spectrum of FIG. 31A .
2. The crystalline naltrexone dichloromethane solvate of claim 1 which is characterized by the x-ray powder diffraction patter of FIG. 7A .
3. The crystalline naltrexone dichloromethane solvate of claim 1 which is characterized by the differential scanning calorimetry thermogram of FIG. 19A .
4. The crystalline naltrexone dichloromethane solvate of claim 1 which is characterized by the IR-ATR spectrum of FIG. 31A .
5. The crystalline naltrexone dichloromethane solvate of claim 1 which is characterized by
(a) the x-ray powder diffraction patter of FIG. 7A ;
(b) the differential scanning calorimetry thermogram of FIG. 19A ; and
(c) the IR-ATR spectrum of FIG. 31A .
6. A crystalline naltrexone dichloromethane solvate which is characterized by at least one of:
(a) the x-ray powder diffraction pattern of FIG. 7B ;
(b) the differential scanning calorimetry thermogram of FIG. 19B ; and
(c) the IR-ATR spectrum of FIG. 31B .
7. The crystalline naltrexone dichloromethane solvate of claim 6 which is characterized by the powder diffraction pattern of FIG. 7B .
8. The crystalline naltrexone dichloromethane solvate of claim 6 which is characterized by the differential scanning calorimetry thermogram of FIG. 19B .
9. The crystalline naltrexone dichloromethane solvate of claim 6 which is characterized by the IR-ATR spectrum of FIG. 31B .
10. The crystalline naltrexone dichloromethane solvate of claim 6 which is characterized by
(a) the x-ray powder diffraction pattern of FIG. 7B ;
(b) the differential scanning calorimetry thermogram of FIG. 19B ; and
(c) the IR-ATR spectrum of FIG. 31B .
11. A pharmaceutical composition comprising the crystalline naltrexone dichloromethane solvate of claim 6 .
12. A pharmaceutical composition comprising the crystalline naltrexone dichloromethane solvate of claim 1 .